Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vandetanib with Chemoradiotherapy for High-Risk Postoperative Head and Neck Cancer
NCT00720083Phase 2Terminated
- Sponsor
- NRG Oncology
- Start
- Nov 2008
- Primary completion
- Aug 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vandetanib in head and neck squamous cell carcinoma (HNSCC), sponsored by NRG Oncology. Started Nov 2008; status: terminated.
02
Drugs
vandetanib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT00720083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00720083.